Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXG-5003 safety and immunogenicity study in healthy Japanese adults
jRCT2041210013Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2021
- Modality
- mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Trial of EXG-5003 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Anti-RBD antibody titers, Neutralizing antibody titers and 2 more. Started May 2021; status: completed.
02
Drugs
EXG-5003
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2041210013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210013.